WU, XIAODAN
WU, XIAODAN
Universita' degli Studi di MILANO
Mostra
records
Risultati 1 - 3 di 3 (tempo di esecuzione: 0.0 secondi).
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
2026 G. Curigliano, X. Hu, R. Dent, K. Yonemori, C.H. Barrios, J. Pierga, F. Puglisi, J. Ferrero, K.H. Jung, N.A. Bagegni, J. Collignon, M. Gil-Gil, X. Wu, A. Andrzejuk-Ćwik, M. Schwaederle, S. Anand, A. Bardia
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial
2025 X. Hu, G. Curigliano, K. Yonemori, A. Bardia, C.H. Barrios, J. Sohn, C. Lévy, W. Jacot, J. Tsurutani, A. Roborel De Climens, X. Wu, A. Andrzejuk-Ćwik, Z. Mbanya, R. Dent
THE ENFORCEMENT OF JUDGEMENTS IN INTERNATIONAL HUMAN RIGHTS COURT
2011 X. Wu